PubMed Health⌕ Search

Biomedical subjects

S Keppens

Publications and source records attributed to S Keppens.

At least 19 recordsLinked to original sources

The level of the glycogen targetting regulatory subunit R5 of protein phosphatase 1 is decreased in the livers of insulin-dependent diabetic rats and starved rats.

Hepatic glycogen synthesis is impaired in insulin-dependent diabetic rats owing to defective activation of glycogen synthase by glycogen-bound protein phosphatase 1 (PP1). The identification of three glycogen-targetting subunits in liver, G(L), R5/PTG and R6, which form complexes with the catalytic subunit of PP1 (PP1c), raises the question of whether some or all of these PP1c complexes are subject to regulation by insulin. In liver lysates of control rats, R5 and R6 complexes with PP1c were found to contribute significantly (16 and 21% respectively) to the phosphorylase phosphatase activity associated with the glycogen-targetting subunits, G(L)-PP1c accounting for the remainder (63%). In liver lysates of insulin-dependent diabetic and of starved rats, the phosphorylase phosphatase activities of the R5 and G(L) complexes with PP1c were shown by specific immunoadsorption assays to be substantially decreased, and the levels of R5 and G(L) were shown by immunoblotting to be much lower than those in control extracts. The phosphorylase phosphatase activity of R6-PP1c and the concentration of R6 protein were unaffected by these treatments. Insulin administration to diabetic rats restored the levels of R5 and G(L) and their associated activities. The regulation of R5 protein levels by insulin was shown to correspond to changes in the level of the mRNA, as has been found for G(L). The in vitro glycogen synthase phosphatase/phosphorylase phosphatase activity ratio of R5-PP1c was lower than that of G(L)-PP1c, suggesting that R5-PP1c may function as a hepatic phosphorylase phosphatase, whereas G(L)-PP1c may be the major hepatic glycogen synthase phosphatase. In hepatic lysates, more than half the R6 was present in the glycogen-free supernatant, suggesting that R6 may have lower affinity for glycogen than R5 and G(L)

Amino Acid Sequence↗

The somatostatin analogue TT-232 induces apoptosis in A431 cells: sustained activation of stress-activated kinases and inhibition of signalling to extracellular signal-regulated kinases.

TT-232 is a somatostatin analogue containing a five-residue ring structure. The present report describes TT-232-induced signalling events in A431 cells, where a 4-h preincubation with the peptide irreversibly induced a cell death program, which involves DNA-laddering and the appearance of shrunken nuclei, but is unrelated to somatostatin signalling. Early intracellular signals of TT-232 include a transient two-fold activation of the extracellular signal-regulated kinase (ERK2) and a strong and sustained activation of the stress-activated protein kinases c-Jun NH(2)-terminal kinase (JNK)/SAPK and p38MAPK. Blocking the signalling to ERK or p38MAPK activation had no effect on the TT-232-induced cell killing. At the commitment time for inducing cell death, TT-232 decreased EGFR-tyrosine phosphorylation and prevented epidermial growth factor (EGF)-induced events like cRaf-1 and ERK2 activation. Signalling to ERK activation by FCS, phorbol 12-myristate 13-acetate (PMA) and platelet-derived growth factor (PDGF) was similarly blocked. Our data suggest that TT-232 triggers an apoptotic type of cell death, concomitant with a strong activation of JNK and a blockade of cellular ERK2 activation pathways.

Antineoplastic Agents↗

Nuclear and subnuclear targeting sequences of the protein phosphatase-1 regulator NIPP1.

NIPP1 is a nuclear subunit of protein phosphatase-1 (PP1) that colocalizes with pre-mRNA splicing factors in speckles. We report here that the nuclear and subnuclear targeting of NIPP1, when expressed in HeLa cells or COS-1 cells as a fusion protein with the enhanced-green-fluorescent protein (EGFP), are mediated by distinct sequences. While NIPP1-EGFP can cross the nuclear membrane passively, the active transport to the nucleus is mediated by two independent nuclear localization signals in the central domain of NIPP1, which partially overlap with binding site(s) for PP1. Furthermore, the concentration of NIPP1-EGFP in the nuclear speckles requires the 'ForkHead-Associated' domain in the N terminus. This domain is also required for the nuclear retention of NIPP1 when active transport is blocked. Our data imply that the nuclear and subnuclear targeting of NIPP1 are controlled independently.

Amino Acid Sequence↗

Specific features of glycogen metabolism in the liver.

Although the general pathways of glycogen synthesis and glycogenolysis are identical in all tissues, the enzymes involved are uniquely adapted to the specific role of glycogen in different cell types. In liver, where glycogen is stored as a reserve of glucose for extrahepatic tissues, the glycogen-metabolizing enzymes have properties that enable the liver to act as a sensor of blood glucose and to store or mobilize glycogen according to the peripheral needs. The prime effector of hepatic glycogen deposition is glucose, which blocks glycogenolysis and promotes glycogen synthesis in various ways. Other glycogenic stimuli for the liver are insulin, glucocorticoids, parasympathetic (vagus) nerve impulses and gluconeogenic precursors such as fructose and amino acids. The phosphorolysis of glycogen is mainly mediated by glucagon and by the orthosympathetic neurotransmitters noradrenaline and ATP. Many glycogenolytic stimuli, e.g. adenosine, nucleotides and NO, also act indirectly, via secretion of eicosanoids from non-parenchymal cells. Effectors often initiate glycogenolysis cooperatively through different mechanisms.

Amino Acids↗

Effects of diadenosine triphosphate and diadenosine tetraphosphate on rat liver cells. Differences and similarities with ADP and ATP.

Liver cells possess multiple types of purinoceptors that mediate the effects of extracellular nucleotides. Like ADP and ATP, the dinucleotides diadenosine triphosphate (Ap3A) and diadenosine tetraphosphate (Ap4A) fully activated glycogen phosphorylase, with ED50 values of 0.31 microM and 1.3 microM, respectively. At variance with ATP, neither the dinucleotides nor ADP significantly increased the levels of IP3.Ap4A (and also ADP) moderately increased IP3 (+/- 72%) whereas Ap3A was completely ineffective. Like ATP, Ap3A, Ap4A, and ADP inhibited the cAMP increase after glucagon. Phorbol-12-myristate-13-acetate (PMA) pretreatment of the hepatocytes clearly inhibited the glycogenolytic potency of Ap3A and ADP, but had only a minor effect on the potency of Ap4A or ATP. It is concluded that, depending upon the effect studied (glycogenolytic effect with or without PMA, increasing IP3 potency, or inhibition of cAMP increase), different analogies between the agonists studied emerged, indicating the complexity of the interaction of ATP and its analogues with liver purinoceptors and/or of the transduction mechanism(s) initiated by the different nucleotides.

Animals↗

Modulation of basal hepatic glycogenolysis by nitric oxide.

We perfused livers from fed rats with a balanced salt solution containing 1 mmol/L glucose. Under these conditions a low steady rate of glycogenolysis was observed (approximately 1.7 micromol glucose equivalents/g/min; 20% of the maximal glycogenolytic activity). Nitric oxide (NO) transiently stimulated hepatic glucose production. A maximal response (on average doubling basal glucose output) was observed with 34 micromol/L NO. The same concentration of nitrite (NO2-) was ineffective. Half-maximal effects were seen at 8 to 10 micromol/L NO, irrespective of the flow direction (portocaval or retrograde). This glycogenolytic response to NO corresponded to a partial activation of phosphorylase. The NO effect was not additive to maximal stimulation of glycogenolysis (7.7 +/- 0.2 micromol hexose equivalents/g/min; n = 4) by 100 micromol/L dibutyryl cyclic adenosine monophosphate (Bt2cAMP). The requirement for activation of phosphorylase was also evidenced by the ineffectiveness of NO in phosphorylase-kinase-deficient livers of gsd/gsd rats. The NO effect was blocked by co-administration of cyclooxygenase inhibitors (50 micromol/L ibuprofen, 50 micromol/L indomethacin, or 2 mmol/L aspirin), suggesting a mediatory role of prostanoids from nonparenchymal cells. This conclusion was confirmed by the fact that NO did not activate phosphorylase in isolated hepatocytes. Moreover, NO was no longer glycogenolytic in livers perfused with Ca2+-free medium, in agreement with the known mediatory role of Ca2+ in prostanoid-mediated responses. Surprisingly, in Ca2+-free medium NO inhibited the basal glucose production. This coincided with an increased elution of cyclic guanosine monophosphate (cGMP). Inhibition of glycogenolysis by NO under these conditions was blocked by 1 mmol/L theophylline, suggestive for involvement of cGMP-stimulated cAMP phosphodiesterase. However, we could not confirm that an increase in cGMP resulted in a drop in cAMP. In conclusion, NO recruits opposing mechanisms with respect to modulation of basal hepatic glycogenolysis. In the presence of Ca2+, activation of phosphorylase with stimulation of glycogenolysis dominates. Cyclooxygenase inhibitors abolish this effect. Activation by NO of the cyclooxygenase in nonparenchymal cells is a distinct possibility. In the absence of Ca2+, inhibition of basal glycogenolysis becomes observable. It remains to be established whether this results from cGMP-mediated stimulation of hydrolysis of cAMP.

Animals↗

Some P2 purinergic agonists increase cytosolic calcium but not inositol 1,4,5-trisphosphate in isolated rat hepatocytes.

Based on the capacity to increase IP3 (inositol 1,4,5-trisphosphate), P2 purinergic agonists can be subdivided into two classes: ATP, ADP, UTP, 2deoxyATP, NAD and GTP significantly increased IP3 levels whereas ADP beta S, 2MeSATP, NADP, alpha, beta MeATP, beta, gamma MeATP and ATP alpha S had only a minor, non-significant effect. Irrespective of their potency to increase IP3, all agonists were full glycogenolytic agonists and they all increased cytosolic calcium. With ATP and NAD, IP3 increasing agonists, and 2MeSATP and ADP beta S, non-IP3 increasing agonists, we found that the initial calcium response appeared to be an 'all or none' phenomenon, small amounts of the agonists being either ineffective or equally effective as high amounts. The minimal amount of an agonist needed to initiate a calcium increase and to promote glycogenolysis was very similar. In the absence of extracellular calcium, both groups of purinergic agonists (tested with ATP and 2MeSATP) were equally able to release calcium from intracellular stores. Cells with emptied intracellular calcium stores rapidly took up extracellular calcium upon treatment with ATP or 2MeSATP, the latter being the most potent. It seems therefore that all nucleotides tested increased cytosolic calcium and activated phosphorylase in a very similar way but some nucleotides had no effect on the levels of IP3.

Animals↗

Effect of genistein on both basal and glucagon-induced levels of cAMP in rat hepatocytes.

Using rat liver hepatocytes, we studied the effect of the tyrosine kinase inhibitor genistein on the Ca2+/IP3 (inositol 1,4,5-trisphosphate) and the cAMP (adenosine 3:5-cyclic monophosphate) transduction mechanisms. Genistein specifically blocked the activation of glycogen phosphorylase after EGF (epidermal growth factor). Genistein on its own partially activated phosphorylase and inactivated glycogen synthase. Genistein did not influence levels of IP3, but increased those of cAMP. This was especially clear when genistein was given together with glucagon. The data suggest an effect of a tyrosine kinase on the synthesis/degradation of cAMP.

Animals↗

Regulation of glycogen phosphorylase activity in isolated human hepatocytes.

Hepatocytes were isolated from human liver tissue by a two-step perfusion technique. They were treated with vasopressin, angiotensin, ATP and phenylephrine, which are known to be Ca(2+)-mediated glycogenolytic agents in rat liver tissue, and as a control, they were treated with the cyclic AMP-mediated hormones glucagon and isoproterenol. All agonists induce a time-dependent activation of glycogen phosphorylase. Glucagon and isoproterenol induce a somewhat higher degree of phosphorylase activation compared with vasopressin, angiotensin, ATP and phenylephrine, which all increase inositol tris-phosphate levels and have no effect on the cyclic AMP levels. The total activity of glycogen phosphorylase (a + b), amounting to 30 to 35 mU/mg protein, is found to be much lower than that found in rat liver tissue. Because only minor differences could be found, we conclude that the regulation of glycogen phosphorylase in human liver tissue is basically the same as that found in rat liver tissue.

Adenosine Triphosphate↗

The complex interaction of ATP and UTP with isolated hepatocytes. How many receptors?

1. ATP exerts multiple receptor-mediated effects on isolated hepatocytes: glycogenolysis through the activation of glycogen phosphorylase (cAMP-independent, IP3/calcium-mediated), inactivation of glycogen synthase, inhibition of the glucagon effect on cAMP, activation of phospholipase D. The fact that some of these effects can be selectively altered and that they are not, or differently, reproduced by some other analogues of ATP, suggests the presence of more than one receptor. (i) Pertussis toxin abolishes the anti-glucagon effect of ATP without affecting its glycogenolytic effect. (ii) Single cell calcium measurements reveal major differences between ATP and ADP, (iii) 2MeSATP and ADP beta S, in clear contrast to ATP, barely increase the levels of IP3 and their glycogenolytic effects is completely blocked by phorbol ester treatment of hepatocytes. (iv) 2MeSATP differs from ADP beta S since it has no anti-glucagon effect. 2. Effects of UTP on isolated hepatocytes so far do not show any difference with effects of ATP, suggesting interaction with the same receptor(s). 3. It is proposed that liver plasma membranes contain (at least) three different receptors mediating (a) the activation of phospholipase C, (b) the activation of phospholipase D and (c) the inhibition of adenylate cyclase.

Adenosine Triphosphate↗

Characterization of the effects of adenosine 5'-[beta-thio]-diphosphate in rat liver.

1. In rat liver cells micromolar concentrations of adenosine 5'-[beta-thio]diphosphate (ADP beta S), activate glycogen phosphorylase by an adenosine 3':5'-cyclic monophosphate (cyclic AMP)- independent mechanism. 2. As with adenosine 5'-triphosphate (ATP), ADP beta S also inhibits the rise in cyclic AMP after glucagon. 3. Cytosolic Ca2+ measured in single cells is rapidly increased with a pattern similar for ADP beta S and for ATP. 4. At variance with ATP, ADP beta S hardly increases inositol 1,4,5-trisphosphate (IP3) levels. 5. Phorbol myristic acetate, which inhibits only slightly the glycogenolytic effect of ATP, almost completely abolishes this effect of ADP beta S. 6. With adenosine 5'-[beta-[35S]thio]diphosphate (ADP beta[35S]) as radioligand, we detected specific purinoceptors on rat liver plasma membranes. Binding consists of a major binding component with KD = 0.7 microM and Bmax = 51 pmol mg-1 of protein, probably mediating the activation of glycogen phosphorylase, and a minor high affinity, low capacity binding component with no obvious function. 7. It is concluded that the differences in biological effects between ATP and ADP beta S may involve different receptors and/or different transduction mechanisms and that ADP beta[35S] can be used to detect the specific binding sites for ADP beta S.

Adenosine Diphosphate↗

Extracellular ATP and UTP exert similar effects on rat isolated hepatocytes.

1. Extracellular UTP and ATP show obvious similarities in their control of several metabolic functions of rat isolated hepatocytes. 2. They have a similar time-course and concentration-dependency for the activation of glycogen phosphorylase, the generation of inositol trisphosphate (IP3), the inhibition of glycogen synthase and the lowering of adenosine 3':5'-cyclic monophosphate (cyclic AMP) levels. 3. There is a similar synergism of the nucleotides with glucagon in activating phosphorylase. 4. They undergo a similar inhibition by phorbol myristic acid of their glycogenolytic effect. 5. The ATP and UTP effect on IP3 levels are not additive. 6. It is tentatively concluded that UTP and ATP use a common receptor.

Adenosine Triphosphate↗

Characterization of the biological effects of 2-methylthio-ATP on rat hepatocytes: clear-cut differences with ATP.

1. In several tissues, 2-methylthio adenosine triphosphate (2MeSATP) is a very potent P2y-purine agonist. In rat hepatocytes, 2MeSATP half-maximally activated glycogen phosphorylase at 20 nM and was therefore about 25 times more effective than ATP (Ka 0.5-0.8 microM). This strong glycogenolytic potency of 2MeSATP suggests on its own the presence of P2Y-purinoceptors in liver. 2. Displacement of the radioligand ATP alpha[35S] from its receptor however occurred at much higher concentrations of 2MeSATP than was anticipated on the basis of its glycogenolytic potency. 3. The interaction of 2MeSATP with the receptor, characterized with ATP alpha[35S] as radioligand, cannot be considered as a pure competitive interaction. 4. 2MeSATP did not share the ability of ATP to counteract the effect of glucagon on the adenosine 3':5'-cyclic monophosphate levels. 5. 2MeSATP barely increased the levels of inositol trisphosphate (IP3). 6. The glycogenolytic effect of 2MeSATP was completely abolished by pretreatment of the hepatocytes with phorbol myristic acetate. 7. It is tentatively concluded that 2MeSATP and ATP are interacting with different P2 purinoceptors.

Adenosine Triphosphate↗

Characterization of the purinoceptors present in rabbit and guinea pig liver.

Micromolar concentrations of ATP induced a cAMP-independent glycogenolytic response in rabbit and guinea pig hepatocytes. With ATP alpha[35S] (adenosine 5'-[alpha-[35S]thio]triphosphate) as radioligand, we detected the presence of specific purinoceptors on hepatocytes and liver plasma membranes of both species. We determined a Kd value of 0.28 microM and a Bmax of 4.8 pmol/10(6) cells for rabbit hepatocytes and a Kd of 0.25 microM and a Bmax of 7.0 pmol/10(6) cells for guinea pig hepatocytes. The Kd values with purified plasma membranes from rabbit and guinea pig liver, were respectively 0.2 and 0.1 microM whereas the Bmax values were respectively 71 and 47 pmol/mg of protein. These purinoceptors belong to the P2Y-subclass as is evidenced by the high degree of similarity which exists between the binding affinities of several ATP analogues to either rabbit or guinea pig liver plasma membranes and rat liver plasma membranes, previously shown to possess P2Y-purinoceptors.

Adenosine Triphosphate↗

Characterization of purinoceptors present on human liver plasma membranes.

Using ATP alpha 35S as radioligand, we have detected the presence of specific purinoceptors on human liver plasma membranes. They are characterized by a Kd value of 0.19 microM and a Bmax of 24 pmol/mg membrane protein. These purinoceptors belong to the P2Y subclass as demonstrated by the high degree of similarity with rat liver purinoceptors, previously shown to be P2Y [(1986) Biochem. J. 240, 367-371] and known to be involved in the control of liver glycogenolysis.

Adenosine Diphosphate↗

Lack of V1 vasopressin receptors in rabbit hepatocytes.

Vasopressin does not induce glycogenolysis in rabbit hepatocytes; glucagon, angiotensin, phenylephrine and ATP are as potent as with rat hepatocytes, whereas isoprenaline is nearly 10000 times more potent in the rabbit. Binding studies of [3H]vasopressin reveal the complete absence of specific vasopressin receptors on rabbit liver plasma membranes. We verified that vasopressin acts as an antidiuretic and vasopressor agent in the rabbit. We conclude that there is a selective lack of V1 vasopressin receptors in rabbit liver.

Animals↗

The angiotensin II receptor of rabbit liver: characterization in isolated hepatocytes and effect of GTP.

A homologous population of specific angiotensin II receptors is present on the cell surface of isolated rabbit hepatocytes. The binding characteristics of [3H]angiotensin II to the cells were: association rate constant (K+1) 0.08 l/nmol per min and dissociation rate constant (K-1) 1.9/min, yielding a dissociation constant (Kd) of 24 nmol/l. A very similar Kd (32 nmol/l) has been derived from saturation binding data which indicate a maximal binding capacity of about 200,000 sites/cell. Analysis of the association binding data to purified liver plasma membranes indicated a Kd of 6 nmol/l in the absence and 30 nmol/l in the presence of GTP. Dissociation was clearly dependent upon the presence of the nucleotide, which shifted the K-1 from 0.12/min to 0.42/min. The studied binding sites are very likely to be involved in the glycogenolytic action of angiotensin II, since a highly significant correlation was established between the biological activity (activation of glycogen phosphorylase) and the binding affinity of a series of agonistic analogues. The reported characteristics of the rabbit hepatic angiotensin II receptors show much similarity with those of rat liver.

Angiotensin II↗